Pruritus in pediatric patients with atopic dermatitis: a multidisciplinary approach - summary document from an Italian expert group

May El Hachem, Giuseppe Di Mauro, Roberta Rotunno, Simona Giancristoforo, Cristiana De Ranieri, Carla Maria Carlevaris, Maria Carmen Verga and Iride Dello Iacono

Abstract

Given the inadequate overall awareness of the main disease features and treatment modalities of pruritus in pediatric patients with atopic dermatitis, a multidisciplinary Italian expert group met with the major aim of increasing knowledge of the condition for improved diagnosis and better management among specialists involved in disease management. Herein, the overall features of the condition are reviewed, along with its etiopathogenesis and symptoms. Likewise, management options are summarized, emphasizing the need for a multidisciplinary approach, minimally composed of a management team that includes a pediatrician, dermatologist, psychologist, play assistant, and dedicated nurse. In addition to more traditional therapies such as emollients as highlighted by European guidelines, therapeutic patient education in a group or individually is highly encouraged as it helps patients and their parents to better understand the disease and provide practical guidance for dressing and bandaging. It can also aid in outlining coping strategies for itching and sleep disturbance. The utility of distraction techniques should also be stressed as such educational interventions involving the child and their parents can substantially improve the overall quality of life. All approaches should be tailored according to patient age and clinical features and requires individualized strategy to ensure good adherence by both children and their parents. Thus, a holistic approach embracing systemic, topical and psychological interventions is advocated in order to provide patients and their caregivers the best possible care.

Keywords: Atopic dermatitis, Pruritus, Multidisciplinary approach, Therapeutic patient education

Introduction

Atopic dermatitis (AD) is a chronic multifactorial disorder that requires multidisciplinary management [1, 2]. The recent literature confirms that the treatment of itching is a challenge. Unfortunately, opinions and approaches are discordant among physicians from the same or different specialties. This can cause confusion for patients and families with implications for decreased adherence to treatment and worsening of disease complications such as lichenification, infection, and sleep disturbance, which negatively affects the overall quality of life (QoL). The therapeutic approach should be adapted to patient age and clinical features and requires a patient-tailored strategy to ensure good compliance by both children and their parents. Considering this aim, an Italian expert group has developed this document as a tool to different specialists involved in disease management (pediatrician, dermatologist, allergologist, psychologist, psychotherapist, play assistant, and nurses) to plan adequate and tailored treatment for each AD patient and itching. Herein, we provide a concise summary document that is relevant for practicing clinicians.
Clinical features and differential diagnosis of AD
AD is most common during childhood [2]. The diagnosis of AD is generally easy and based on clinical features that vary upon patient age and disease severity (Table 1). In addition, other signs and symptoms may be associated and are helpful to confirm the diagnosis in some patients (Table 2). Differential diagnosis is always necessary and arises in a list of diseases from variable severity requiring different management approaches (Table 3).

The etiopathogenesis of itching in AD
Pruritus is the major and disrupting symptom of AD and is due to a complex interaction comprising skin barrier deficiency, immunological dysfunction, and central and peripheral neural mechanisms. Itching promotes a negative cycle described as “the itch that rashes” [2, 3]. Scratching causes further damage to the skin barrier, stimulating skin inflammation and inducing factors called pruritogens. (Fig. 1) This mechanism leads to the development, progression, chronicity of AD, and complications [3, 4]. The main etiopathogenetic factors are summarized below as follows:

- Skin barrier disruption. AD is characterized by systematic epidermal barrier dysfunction; due to, at first, tight junction aberration with reduced expression of some claudins and zonulins. In addition, several mutations in the filaggrin gene have been identified. This filament is essential for controlling transepidermal water loss (TEWL) and maintaining stratum corneum organization and hydration [3–5]. Itch intensity in AD is associated with increased TEWL. Filaggrin deficiency also leads to an increase in cutaneous pH, which enhances the function of kallikreins, or serine proteases known as pruritogens that are upregulated in AD [3, 6]. Moreover, epidermal barrier dysfunction allows for entry of irritants and pruritogens [6, 7].
- Immunological disorder. Skin barrier dysfunction and inflammation lead to an aberrant type 2 immune response, with increased IgE production, eosinophilia, mast cell activation, and overexpression of Th2 cytokines (IL-4, IL-5, IL-13). This cascade promotes production of epithelial-derived cytokines, namely, thymic stromal lymphopoietin (TSLP). TSLP influences innate lymphoid cells (ILCs) and increases the production of Th2 chemokines [4, 5, 8].
- Hyperinnervation of skin and central sensitization of itch. An increase in nerve fiber density in the epidermis reported in AD, which is partly explained by the increase in nerve growth factor observed in the plasma of AD patients. Moreover, some studies have implicated involvement of central nervous system structures and astrocytes in sensitization of itch. Other studies have revealed a central neural circuit that is critical for signal processing of itch [9, 10].
- Itch mediators/pruritogens. The sensation of itching is mediated by cytokines, neuropeptides, and endogenous secreted factors. These itch-inducing factors act on sensory neurons to drive itch sensation. Histamine is one of the earliest identified pruritogens; among four receptors, H1R and H4R are potential mediators of pruritus. Others endogenous and exogenous factors produced from inflammation and xerosis result in the induction of non-histaminergic itch (i.e. protease astyptase, dust mites, Staphylococcus aureus, or substance P, TSLP, Notch proteins) [5–7, 11]. Recently, a role of IL-31 produced by Th2 cells has been recognized in inducing itch [12, 13].

Symptoms and complications

| Table 1 Characteristic features of atopic dermatitis by age. Modified from Ref. [1] |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| AD                              | Infant                          | Childhood                       | Adolescent or Adult             |
| Lesions                         | Exudative erythematous weepy papules and plaques | Weepy erythematous papules and plaques intermixed with lichenified plaques, particularly in flexural areas | Erythematous papules and plaques with xerotic scale and crust |
| Distribution                    | Scalp, face (without perioral and periorbital involvement) trunk, extensor surfaces | Flexural surfaces, including antecubital and popliteal fossa, wrist, and neck | Hands, flexural surfaces, upper trunk |

Sensations:
- histamine
- cytokines
- mast cells
Severity Index (EASI), the global assessment of the investigator (IGA), and the SASSAD (Six Area, Six Sign Atopic Dermatitis) [16].

The tools used for assessment of the intensity of itching are the Visual Analogue Scale (VAS), Numerical Scale, Verbal Scale, and Itching Severity Scale (ISS). However, there is no gold standard instrument for accurate assessment of the intensity and severity of pruritus and it is widely recommended that at least two should be used for reliable judgment [17].

**Complications**

In patients with DA, constant pruritus can lead to chronicity with the appearance of nummular eczema, lichenification and/or nodular prurigo. Bacterial and viral superinfections are a frequent complication due to altered skin barrier and itching. In addition, scratching may induce autoinoculation, particularly in the presence of molluscum contagiosum and impetigo [18]. (Fig. 2).

The persistence of pruritus, sleep disturbance, and worsening of skin conditions have a negative impact on psychological development of the child and on the emotional status of both the child and his/her parents, affecting daily activities, social relationships, and quality of life. In some cases, care to the AD patient may generate a conflict between the parents and the non-affected children, who may feel neglected.

In some situations, targeted psychological intervention may be necessary. It is appropriate to suggest this in the presence of: (i) strongly involved parents (disproportion between the problem and its consequences), (ii) excessive influence of the disease on

**Table 2** Associated features of atopic dermatitis. Modified from Ref. [1]

| Feature                        | Description                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|
| Pityriasis alba                | Hypopigmented patches on face, upper trunk, upper extremities              |
| Keratosis pilaris              | Follicular hyperkeratosis of outer arms, lateral cheeks, buttocks, thighs   |
| Dennie-Morgan fold             | Extra line on lower eyelid                                                 |
| Allergic shiners               | Violaceous to gray color of infraorbital area                              |
| Hyperlinear palms              | Increased and exaggerated skin markings on palms                            |
| Ichthyosis vulgaris            | Scaling of extensor extremities, fish-scale appearance of extensor leg     |
| Hertoghe sign                  | Loss of lateral eyebrows                                                   |
| White dermatographism          | Blenching of skin after stroking                                           |
| Circumoral pallor             | Pallor of perioral area                                                    |
| Nummular dermatitis           | Sharply circumscribed thick coin-shaped scaly plaques                      |

**Table 3** Atopic dermatitis and differential diagnosis. Modified from Ref. [1]

| Disease                      | Age               | Morphology                                                                 | Distribution                                                                 | Symptoms                 |
|------------------------------|-------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------|
| AD                           | Childhood         | Erythematous eczematous weepy plaque with fine dry scale                  | Face, scalp, Extensor surfaces in infants, flexural surfaces in children, trunk, nails | Severe pruritus           |
| Seborrheic dermatitis        | Any age           | Salmon-pink fine papules coalescing into poorly defined plaques with variable greasy scaling | Face, scalp, Retroauricular folds, neck, axillae, inguinal folds            | Absent to mild-moderate pruritus |
| Psoriasis                    | Any age           | Well-demarcated, pink plaques with adherent silvery scale, confluent bright red plaque with sharply defined borders and relative lack of scale | Extensor surface of joints (elbows, knees) and extremities, Retroauricular folds, axillae, umbilicus, diaper area, inguinal folds, genitalia, gluteal cleft, nails | Mild-moderate pruritus    |
| Allergic contact dermatitis  | Any age, incidence increases with age | Geometric erythematous eczematous weepy plaques | Based on exposure                                                                 | Severe pruritus           |
| Scabies                      | Any age           | Poorly defined erythematous papules, nodules, burrows, pustules, and vesicles | Wrist spaces, interdigital spaces, axillae, umbilicus, nipples, diaper area  | Severe nocturnal pruritus |
| Mycosis fungoides            | Adulthood, Hypopigmented MF More common in children | Erythematous patches, papules, or plaques with subtle scale; polycyclic or annular, hypopigmented patches, often with fine scaling | Buttock, lower trunk, thighs, breasts, and groin | Pruritus                  |
| Dermatomyositis              | Childhood and middle age | Violaceous scaly papules, Periorbital violaceous edema | Small joints of hands and elbows, face | Myositis                  |
| Immunodeficiency and metabolic disorders | Infancy | Eczema or eczema-like eruption, erythroderma | Spread, resistant to treatment | Other cutaneous and extracutaneous manifestations Blood testing and genetic investigations upon diagnostic hypothesis |
daily life and interpersonal relationships, (iii) parent/child relationships characterized by mutual dependence, and (iv) psychological issues in a family member or in the functioning of the family nucleus.

**Therapeutic patient education**

The WHO defines therapeutic patient education (TPE) as a continuous process to train and guide the patient and his/her family to acquire the competencies needed to manage his/her chronic disease. TPE is mandatory for adequate management of AD and itching for several reasons:

- AD is a multidisciplinary disease with discordant opinions between specialists
- clinical features are polymorphic in the same day in the same patient
- early age of disease onset
- lack of specific treatment against pruritus
- sleep disturbance involving the family
- scarce compliance due to chronicity, time and costs for dressing
- esthetic damage
- psychosocial impact

TPE should be performed within the multidisciplinary approach required for AD. The specifically trained team should be minimally composed of a pediatrician, dermatologist, and dedicated nurse. In some cases, a psychologist is also required. All specialists should use the same language and provide the patient/family with a specific and tailored educational program. When required, other professional categories (e.g. allergologist) should be informed and take part in the TPE.

TPE can be performed within a group or individually and comprises:

- a theoretical aspect explaining the disease, its evolution and stressing its benign prognosis
- providing specific educational leaflets to the parents and children with adequate language
- a practical demonstration of dressing, patient massage, bandaging etc.
- strategies and tools for coping with itching and sleep disturbance (such as distraction techniques and their illustration)
- continuous evaluation of the patient and family perception
- psycho-diagnostic testing and psychotherapeutic intervention, when required.

A well-integrated and coordinated TPE program ensure adherence to treatment and better control of pruritus and sleep disturbance, thus reducing overall costs and improving QoL [19, 20].

**Medical treatment**

Antipruritic therapy is multidimensional aimed at minimizing symptoms and contributing factors such as dry skin, inflammation, and related scratch lesions. Therefore, several measures can be recommended [16, 18–20]. Treatment of AD improves itching. Evaluation of the efficacy of different therapies on itching is difficult due to multiple components influencing this symptom, including psychological attitude.

Immunotherapy to inhalants is indicated in addition to other topical and/or systemic treatment in order to improve itching and please add the reference [21].

**Topical therapy**

Topical therapy is mandatory to repair skin barrier and reduce itching and skin susceptibility to irritants. Hydration is always essential, even during remission. Several topical products are available, and the selected formulation should be cosmetically acceptable to the patient, and possibly
inexpensive, in order to encourage good compliance. The specific choice of treatment depends on both individual and clinical features [16, 22–24].

**Topical skin care** For all topical skin care, it should be highlighted that specifically formulated products should be used, which are free of preservatives and perfumes [25].

- **Cleansers.** Oil, non-soap, or mild soap cleansers, without perfumes. Sodium hypochlorite (bleach) baths as antiseptic is an additional option [23, 24].
- **Hydration.** Emollients and moisturizers are a mainstay of pruritus management. As undressing could deteriorate itching, emollients should be applied on xerotic/lichenified skin not covered by clothes twice daily, and at least once daily to the entire surface of the skin, and more when undressing children for other reasons. They should be regularly applied, even during remission to prevent itching, flares, and complications [22, 23, 26, 27]. Emollients “plus” are non-medicated products containing active ingredients [28, 29].

**Anti-inflammatory therapy**
- **Corticosteroids:** topical corticosteroids (TCS) are still considered the mainstay of pharmacological treatment and first choice agents for inflammation and itching [18–20, 30, 31].
- **Calcineurin inhibitors:** tacrolimus ointment (0.03 and 0.1%) and pimecrolimus cream (1%) are immunomodulators used for moderate/severe and mild forms, respectively. It is important to take into account the age limit and possible contraindications (immunosuppression, exudative and infected lesions) [18–20, 32, 33].

**Antimicrobial therapy**
- Antimicrobials and antiseptics are necessary to treat infected lesions. Fusidic acid, retapamulin, and mupirocin are the most appropriate antibiotics [34, 35].

**Upcoming topical therapies**
- Topical phosphodiesterase 4 inhibitor, crisaborole, is an effective treatment of mild-to-moderate AD in patients from 2 years of age and is still experimental in Italy [36].
- Topical Janus kinase (JAK) inhibitors are being studied in clinical trials [37].

**Wet dressing, or wet-wrap therapy**
- The application of a topical medication followed by bandaging or wet dressing (a double layer of gauze or tubular dressings, the first layer moistened and the second layer dry) is indicated in exudative, infected or lichenified lesions, and protects against scratching and environmental irritants. It is also useful to promote absorption of topical products. Thus, it is important to take into account possible side effects, especially with concomitant corticosteroids [38, 39].
**Phototherapy**
UV therapy can be used in AD to relief pruritus. Narrowband UV-B and UV-A has been demonstrated to be the most preferable artificial radiation [40, 41].

**Systemic therapy**
Systemic therapies with confirmed effects against pruritus recommended by the guidelines are:

- **Antihistamines.** Short-term and intermittent courses of sedating (first-generation) antihistamines can be used in children if itch strongly affects quality of sleep [42–44].
- **Systemic corticosteroids.** Short courses of therapy may be indicated in special situations [45, 46].
- **Systemic antimicrobial therapy.** Antibiotics should be reserved exclusively for clear signs and symptoms of bacterial infection, and not simple bacterial colonization [45, 47].
- **Oral immunomodulatory therapies.** These are to be used for chronic itching recalcitrant to topical therapy [45, 48–51].
- **Target therapy.** Biologic agents against pathogenic cytokines and their receptors are a relatively new group of therapeutics [45]. Dupilumab (anti IL-4 and 13) is recommended as a disease-modifying drug for moderate-to-severe AD in Europe [52]. Treatments with ustekinumab (anti IL-12 and IL-23), tralokinumab (anti IL-13), or nemolizumab (anti-IL-31) are still experimental [53–56]. Oral drugs such as TSLP antagonists and JAK inhibitors are under development [57, 58]. Their use should be restricted to very selected cases and used in specialized centers.

**Therapeutic patient education follow-up and psychological support**
Despite the increasing prevalence of childhood AD, only a few studies have explored a specific educational approach in the last years. Recent national and international AD guidelines confirm that effective and standardized educational programs should be considered part of AD management and routine care. These treatment strategies are focused on patients and their families. Interventions must be delivered by a multidisciplinary team with an individual face-to-face or group education. The need for education and support will vary according to patient age, socio-cultural behavior, and severity of AD. The educational approach should be preferably focused on families of children below 6 years of age because of the significant and high impact on disease and allow good management following disease onset. It is clear that the motivation to treat is high if the parents receive more (and correct) knowledge about the disease. Parents who play a key role in their children’s treatment can considerably reduce the severity and impact of AD. This suggests that in addition to pharmacological treatment, providing educational support to parents is an important factor in achieving a positive long-term outcome. Less benefit for children more than 6 years with moderate or severe eczema has been reported because they become with time less motivated to treat themselves [59], and for this reason the educational program should start as soon as possible. The treatment of AD should ideally take into consideration both the patient’s physical and emotional aspects and the impact of the disease in personal and family contexts. Attention to the emotional area allows: (i) promotion of a psychological elaboration that integrates information and emotions, facilitating memorization and consolidation of new information; (ii) creation of a relational context in a dedicated area for listening to the patient and his/her parents (knowing what he/she knows, how the patient lives with the illness, how much it influences them and their family); (iii) supporting the resources and skills of the patient and parents. An early start of the training process is important, before any feelings of ineffectiveness and mistrust and/or relationship difficulties and conflicts are established. For management of AD and pruritus, we think that education should be based on an approach that addresses the needs of the child and parents at a level they can comprehend. Educators are dermatologists, pediatricians, nurses and psychologists. The educators’ role with the intervention group is to train, support, and motivate parents and children in self-management. One of the most important interventions in the management of AD is spending time listening to patients’ concerns, explaining its causes, and showing how to apply topical therapies on the basis of clinical features of the lesions and patient age. The application of topical therapies is an essential part of the successful management of pruritus and atopic eczema. Longer consultations and forming a good caregiver-patient relationship are the strongest predictors of adherence to skin-care treatment. Performing this role requires well-trained educators [60].

**Adjuvant therapies: distraction techniques**
Treatment of children with AD and pruritus and adequate management of the daytime and nighttime problems due to itching have a strong impact on the entire family context, making it necessary to focus on emotional and relational aspects. In order to facilitate the management of pediatric patients during application of dressings and to provide tools to deal with frequent itching, the use of specific distraction techniques is crucial. These non-pharmacological procedures with a psychological approach have been described in the literature [61–63], and are especially useful in pain management and during unpleasant procedures and or sensations. These are
cognitive-behavioral techniques, aimed at shifting attention from pruritus and medication towards activities that intensely absorb the patient: the techniques imply active sensory perception, and not just a passive strategy, that can be entertaining the child. The techniques are based on two principles: (i) children have mental boundaries between fantasy and reality that are more fluid and permeable than in adults; (ii) and it is difficult, if not impossible, for a human to focus on more than one or two sensory stimuli at once. A detailed description of distraction techniques by age group along with specific examples is provided as Additional file 1.

The choice of distraction techniques (involvement, breathing, relaxation, hypnotic procedures such as visualization and desensitization) depends on several factors: age, personality, individual likes and dislikes, motivation, and emotions of reference figures. In addition, even the time of day is important since, for example, at night a massage would be favored over watching a cartoon. The application of these tools allows defusing the phenomenon of anticipatory anxiety and increased compliance to treatment. These techniques are useful not only for children, who are the main recipients, but also for parents and siblings. It is therefore important to educate the entire family on their use, and to adapt them in specific situations. Distraction techniques are also helpful to parents to feel more relaxed, they improve the interaction with their child, transmitting greater security and managing the disease with less anxiety. The utility of learning techniques has also been documented in the parents of very young children [59–62].

Conclusions
The focus of the present summary document was to increase awareness of pruritus in pediatric patients with AD. In addition, the authors tried to provide a useful tool for all specialists who managed patient with this disease and pruritus. Emollients, as reported by the literature are considered the backbone in restoring the skin barrier, reducing itching and relapses. The psychological support should be contemplated as one of the several therapeutic options available or on trial. Finally, it is emphasized that a multidisciplinary approach is always necessary to guarantee an adequate management of patients with AD. Moreover, educational interventions can greatly improve reducing symptoms, improving the adherence to treatment and the overall quality of life for both young sufferers and their parents.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13052-020-0777-9.

Additional file 1. Description of distraction techniques by age group.

Abbreviations
AD: Atopic Dermatitis; EASI: Eczema Area and the Severity Index; IGA: Investigator Global Assessment; ILCs: Innate Lymphoid Cells; ISS: Itching Severity Scale; QoL: Overall Quality of Life; SASSAD: Six Area Six Sign Atopic Dermatitis; SCORAD: SCORing Atopic Dermatitis; TCS: Topical Corticosteroids; TEWL: Transepidermal Water Loss; TPE: Therapeutic Patient Education; TSLP: Thymic Stromal Lymphopoietin; VAS: Visual Analogue Scale

Acknowledgements
The authors would like to thank the children affected by AD for their collaboration in the path of therapeutic education and in the fruitful use of distraction techniques. We also thank Mr. Gabriele Bacile for his help with figures. Editorial support was provided by Edra spa, and unconditionally funded by Pierre Fabre.

Authors’ contributions
All authors participated in the and drafting and reviewing the manuscript and read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing of interest.

Author details
1Dermatology Unit, Bambino Gesù Children’s Hospital, IRCCS, Piazza di Sant’Onofrio, 4, 00165 Rome, Italy. 2Primary Care Pediatrics, ASL Caserta, Caserta, Italy. 3Unit of Clinical Psychology, Ospedale Pediatrico Bambino Gesù (IRCCS), Rome, Italy. 4Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. 5Primary Care Pediatrics, ASL Salerno, Vietri sul Mare, Italy. 6Unit of Pediatrics, Fatebenefratelli Hospital, Benevento, Italy.

Received: 18 April 2019 Accepted: 21 January 2020

Published online: 30 January 2020

References
1. Barrett M, Luu M. Differential diagnosis of atopic dermatitis. Immunol Allergy Clin N Am. 2017;37(1):11–34.
2. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–22.
3. Kidō-Nakahara M, Furue M, Ulfz D, Nakahara T. Itch in atopic dermatitis. Immunol Allergy Clin N Am. 2017;37(1):113–22.
4. Furue M, Chiba T, Tsuji G, Uchida D, Kidō-Nakahara M, Nakahara T, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403.
5. Reknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen [Internet]. 2017;3:37 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725464/, [cited 2018 Oct 31].
6. Murota H, Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8–13.
7. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51(3):263–92.
8. Leyva-Castillo JM, Herien P, Micheau P, Karasuyama H, Chan S, Sounelis V, et al. Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. Nat Commun. 2013;4:2847.
9. Mu D, Deng J, Liu X-F, Wu Z-Y, Shi Y-F, Guo W-M, et al. A central neural circuit for itch sensation. Science. 2017;357(6352):695–9.
10. Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol. 2014;41(3):205–12.
59. Liang Y, Tian J, Shen CP, Xu F, Wang H, Li P, et al. Therapeutic patient education in children with moderate to severe atopic dermatitis: a multicenter randomized controlled trial in China. Pediatr Dermatol. 2018;35(1):70–5.

60. Barbarot S, Bernier C, Deleuran M, De Raeve L, Eichenfield L, El Hachem M, et al. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol. 2013; 30(2):199–206.

61. Leibovici V, Magora F, Cohen S, Ingber A. Effects of virtual reality immersion and audiovisual distraction techniques for patients with pruritus. Pain Res Manag. 2009;14(4):283–6.

62. Grillo M, Long R, Long D. Habit reversal training for the itch-scratch cycle associated with pruritic skin conditions. Dermatol Nurs. 2007;19(3):243–8.

63. Han L, Dong X. Itch mechanisms and circuits. Annu Rev Biophys. 2014;43:331–55.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.